Prothena/$PRTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Prothena
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
- Ticker
- $PRTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 67
- Headquarters
- Dublin, Ireland
- Website
- www.prothena.com
Prothena Metrics
BasicAdvanced
$463M
-
-$0.83
-0.35
-
Price and volume
Market cap
$463M
Beta
-0.35
52-week high
$11.80
52-week low
$7.73
Average daily volume
381K
Financial strength
Current ratio
25.048
Quick ratio
24.721
Long term debt to equity
1.405
Total debt to equity
2.437
Profitability
EBITDA (TTM)
-59.04
Gross margin (TTM)
-19.11%
Net profit margin (TTM)
-80.67%
Operating margin (TTM)
-109.79%
Effective tax rate (TTM)
0.81%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
-10.67%
Return on equity (TTM)
-14.39%
Valuation
Price to revenue (TTM)
8.829
Price to book
1.63
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-7.93
Free cash flow yield (TTM)
-12.61%
Free cash flow per share (TTM)
-1.137
Growth
Revenue change (TTM)
427.32%
Earnings per share change (TTM)
-85.19%
3-year revenue growth (CAGR)
-1.83%
10-year revenue growth (CAGR)
44.93%
3-year earnings per share growth (CAGR)
-33.19%
10-year earnings per share growth (CAGR)
-13.37%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Analyst projections of the future price of Prothena stock.
Bulls say / Bears say
Prothena ended Q2 2026 with $289.1 million in cash and no debt, securing sufficient runway to advance its late-stage clinical programs through multiple key inflection points. (SEC)
Phase 2b PADOVA results for Prasinezumab, published in The Lancet, demonstrated exploratory clinical and biomarker signals in early Parkinson’s disease—supporting Roche’s transition to the Phase 3 PARAISO trial. (SEC)
Collaborations with Roche, Novo Nordisk, and Bristol Myers Squibb could generate up to approximately $3 billion in aggregate milestone payments plus royalties, materially de-risking development and offering significant future upside. (TradingView)
Revenue in Q2 2026 was only $1.0 million, underscoring Prothena’s reliance on uneven milestone payments and the resulting volatility in topline performance. (TradingView)
The company projects its year-end cash balance to be approximately $259 million—down from $289.1 million at June 30, implying a burn of about $30 million in H2 2026 that may necessitate dilutive financing if trial costs accelerate or milestones slip. (TradingView)
Key Phase 3 registrational trials for Prasinezumab (PARAISO) and Coramitug (CLEOPATTRA) have primary completion dates not until 2029, deferring any potential commercial launch and revenue generation by at least three years. (TradingView)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Upcoming events
No upcoming events
Prothena News
AllArticlesVideos
Funds containing Prothena
AllUSDEURGBP
Fund name | Fund size | $PRTA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.04% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.04% |
iShares Healthcare Innovation£DRDR | £1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Ageing Population€AGED | €822M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.